All studies
Active not recruitingPHASE3INTERVENTIONAL

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

High cholesterol is a common condition where fatty substances build up in the blood. Over time, this can narrow blood vessels and increase the risk of heart attacks and strokes. This phase 3 trial is an extension study testing a daily tablet called enlicitide decanoate (MK-0616). Enlicitide decanoate works by helping the body clear harmful cholesterol from the bloodstream. While similar medicines are usually given as injections, this experimental medicine comes as a pill. Researchers want to find out how safe and effective it is over a longer period. The study is open only to adults who have already completed one of three earlier trials using this medication and took at least 80% of their prescribed doses. Because it is an open-label trial, all participants will receive the active study medicine. The results will help show if this tablet is a practical, long-term option to protect heart health.

At a glance

Status
Active not recruiting
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Enrolment target
3,000
Start
05 Aug 2024
Estimated completion
13 Oct 2028

What is this study about?

Cholesterol is a waxy fat that your body needs in small amounts. However, having too much "bad" cholesterol (LDL cholesterol) in your blood can cause fatty deposits to build up in your arteries. Over time, this raises your chances of having a heart attack or stroke. While lifestyle changes and common medications like statins help many people, others still need extra help to get their cholesterol down to a safe level.

This trial investigates an experimental medicine called enlicitide decanoate (also known as MK-0616). It belongs to a family of treatments called PCSK9 inhibitors. These medicines stop a specific protein from interfering with your liver's ability to clear bad cholesterol from your blood. Existing PCSK9 treatments must be injected, but enlicitide decanoate is designed as an oral tablet, which may be much more convenient for patients.

Because this is an "extension study", its main goal is to follow people over a longer period to see how well the medicine works long-term and check for any unexpected side effects. Everyone who takes part will receive the real medicine rather than a dummy pill (placebo). The findings will help doctors understand whether this daily pill can safely protect heart health over many years.

Key takeaways

  • This extension study checks the long-term safety and benefits of enlicitide decanoate tablets for high cholesterol.
  • It is only open to adults who fully completed an earlier trial with this medicine.
  • Every participant receives the active study medication; there is no placebo.
  • You will have regular clinic visits and blood tests to monitor your progress.
  • Joining is entirely your choice, and you can stop taking part whenever you wish.

Who may be eligible?

This study is only open to people who have already taken part in and fully completed one of three specific earlier trials for enlicitide decanoate (study codes MK-0616-013, MK-0616-017, or MK-0616-018). You must be 18 years of age or older and have completed all the final health checks required at the end of that first study. You also need to have taken at least 80% of your study pills during that previous trial.

You cannot take part if you had to stop taking the study medication early during your earlier trial, or if you developed a serious side effect linked to the drug that is still ongoing. In addition, you cannot join if you are taking part in any other clinical drug trial or if you plan to start a different, non-study PCSK9 inhibitor medicine.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I fully completed one of the previous enlicitide trials (MK-0616-013, -017, or -018).
  3. I took at least 80% of my trial tablets during the earlier study.
  4. I did not have to stop the trial medicine early due to serious side effects.
  5. I am not currently taking part in any other clinical drug trial.
Answer every question to see your result.

What does participation involve?

If you take part, you will be given enlicitide decanoate tablets to take once a day at home. You will need to attend regular appointments at the study clinic so doctors can monitor your health. During these visits, the study team will carry out routine checks, including blood tests to measure your cholesterol levels and liver function, blood pressure checks, and discussions about how you are feeling. This extension study lasts over a longer period than the earlier trials so researchers can gather long-term safety data. Your study team will give you a clear schedule showing exactly how often you need to visit the clinic and how long your participation will last.

Potential risks and benefits

A potential benefit of joining is that the study tablet may help keep your cholesterol at a healthy level, and your heart health will be closely supervised by medical specialists. However, there is always a chance of unwanted side effects. Because this study looks at longer-term use, there may be side effects that are not yet fully known. Your study doctor will explain all known risks before you agree to continue. Taking part is completely voluntary. You are free to leave the study at any point without giving a reason, and your standard NHS medical care will not be affected in any way.

Locations (222)

  • Alliance for Multispecialty Research, LLC ( Site 0027)
    Verified postcode
    Daphne, United States
  • G&L Research ( Site 0035)
    Verified postcode
    Foley, United States
  • Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0048)
    Verified postcode
    Phoenix, United States
  • National Heart Institute-Research ( Site 0029)
    Verified postcode
    Beverly Hills, United States
  • Clinical Trials Research ( Site 0054)
    Verified postcode
    Sacramento, United States
  • Velocity Clinical Research, Banning ( Site 0023)
    Verified postcode
    San Bernardino, United States
  • Emerson Clinical Research Institute ( Site 0017)
    Verified postcode
    Washington D.C., United States
  • Excel Medical Clinical Trials ( Site 0010)
    Verified postcode
    Boca Raton, United States
  • Alliance for Multispecialty Research, LLC ( Site 0037)
    Verified postcode
    Doral, United States
  • Alliance for Multispecialty Research, LLC ( Site 0056)
    Verified postcode
    Fort Myers, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0053)
    Verified postcode
    Hallandale, United States
  • Jacksonville Center for Clinical Research ( Site 0025)
    Verified postcode
    Jacksonville, United States

Common questions

What does an 'open-label' study mean?

An open-label study means that both you and the research team know you are receiving the real study medicine. There are no dummy pills or placebos in this trial.

Can I join if I was not in one of the earlier enlicitide trials?

No. This extension study is strictly for adults who have already completed one of the three specific parent trials (MK-0616-013, MK-0616-017, or MK-0616-018).

How is this medicine different from other PCSK9 inhibitors?

Most PCSK9 inhibitors currently available are given as injections under the skin. Enlicitide decanoate is designed to be taken by mouth as a tablet.

Does taking part cost anything?

No. The study medication, clinic visits, and all trial-related tests are provided free of charge. Travel expenses to and from the clinic are often covered as well.

What happens if I decide I want to stop?

You can leave the trial at any time. Simply let your study team know. Your regular doctors will help you switch back to standard NHS cholesterol treatments.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.